Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma

Autor: Peter Sminia, Robin M. de Kruijff, Helga E. de Vries, Gabriel Becerril Aragon, Ravi S. Narayan, Susanne M A van der Pol, Guzman Torrelo Villa, Ana Gasol Garcia, Fatima Bikhezar, Ben J. Slotman, Astrid J.G.M. van der Meer, Antonia G. Denkova

Publikováno v: Journal of Neuro-Oncology
Bikhezar, F, de Kruijff, R M, van der Meer, A J G M, Torrelo Villa, G, van der Pol, S M A, Becerril Aragon, G, Gasol Garcia, A, Narayan, R S, de Vries, H E, Slotman, B J, Denkova, A G & Sminia, P 2020, ' Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma ', Journal of Neuro-Oncology, vol. 146, no. 2, pp. 239-246 . https://doi.org/10.1007/s11060-019-03365-y, https://doi.org/10.1007/s11060-019-03365-y
Journal of Neuro-Oncology, 146(2), 239-246. Kluwer Academic Publishers
Journal of Neuro-Oncology, 146(2)

Background and purpose Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas, with an average survival rate of 15 months after diagnosis. More than 90% of all GBMs have activating mutations in the MAPK/ERK pathway. Recentl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e8840323e8547e2aacaf5ef1e7ecc5
http://europepmc.org/articles/PMC6971148